Cargando…
Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma
Multiple myeloma (MM) is a plasma cell malignancy defined by complex genetics and extensive patient heterogeneity. Despite a growing arsenal of approved therapies, MM remains incurable and in need of guidelines to identify effective personalized treatments. Here, we survey the ex vivo drug and immun...
Autores principales: | Kropivsek, Klara, Kachel, Paul, Goetze, Sandra, Wegmann, Rebekka, Festl, Yasmin, Severin, Yannik, Hale, Benjamin D., Mena, Julien, van Drogen, Audrey, Dietliker, Nadja, Tchinda, Joëlle, Wollscheid, Bernd, Manz, Markus G., Snijder, Berend |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212768/ https://www.ncbi.nlm.nih.gov/pubmed/37081258 http://dx.doi.org/10.1038/s43018-023-00544-9 |
Ejemplares similares
-
P856: A SINGLE-CELL FUNCTIONAL PRECISION MEDICINE LANDSCAPE OF MULTIPLE MYELOMA
por: Kropivsek, K., et al.
Publicado: (2022) -
Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis
por: Wildschut, Mattheus H. E., et al.
Publicado: (2023) -
Multiplexed high-throughput immune cell imaging reveals molecular health-associated phenotypes
por: Severin, Yannik, et al.
Publicado: (2022) -
A Conserved Circular Network of Coregulated Lipids Modulates Innate Immune Responses
por: Köberlin, Marielle S., et al.
Publicado: (2015) -
An ex vivo system to study cellular dynamics underlying mouse peri-implantation development
por: Ichikawa, Takafumi, et al.
Publicado: (2022)